• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA issues new draft guidance on Class III de novos, UDI for small entities

FDA issues new draft guidance on Class III de novos, UDI for small entities

August 14, 2014 By Arezu Sarvestani

FDA issues new draft guidance on Class III de novos, UDI for small entities

The FDA issued a pair of new documents this week outlining the agency’s thinking on review of breakthrough medical devices and providing guidance for small companies trying to keep up with the new Unique Device Identifier program.

In a draft guidance proposed today the FDA offered some advice for companies developing novel devices that they believe are low-risk and thus eligible for more lenient review.

Under current FDA law, medical devices that truly have no equivalent or predicate on the market are automatically lumped in the Class III category, where they’re treated as high-risk and subject to the most stringent requirements. The de novo pathway allows manufacturers of unique devices to apply for a more relaxed review, but that used to require that companies 1st attempt and fail to win market clearance through the 510(k) medtech fast-track.

Under new guidelines companies no longer need to pass through the 510(k) pathway before applying for de novo review, a measure that the agency hopes will save time and both on all sides.

In the latest draft guidance the FDA provided some detailed criteria to help manufacturers determine when they may apply for de novo review and what types of materials to provide with their application, including for companies that have already made an attempt through the 510(k) process.

The agency recommended that companies apply for de novo review early through a pre-submission, or pre-sub.

"A pre-sub is not required in order to obtain FDA review of a de novo, but is a useful way for submitters to facilitate early feedback from FDA," according to the draft guidance. "A Pre-Sub would allow FDA to provide feedback on whether a device may be suitable for the de novo process and/or to advise you on the documentation needed in a subsequent de novo."

"The success of a de novo that is filed without a Pre-Sub will depend more heavily on  how well you search for a potential predicate device, identify the risks and special  controls (if applicable), and define and collect adequate data to provide reasonable assurance of safety and effectiveness," the FDA added.

In separate guidance finalized this week the FDA offered advice specific to small entities for compliance with the new Unique Device Identifier (UDI) rules. The new UDI program requires that manufacturers of all applicable medical devices prepare trackable labels and submit data for the FDA’s Global Unique Device Identification Database.

The new report outlines exceptions, details how the UDIs must appear, specifies data-keeping requirements and provides other program information articulated for small companies, defined as manufacturers with 500 or fewer employees or relabelers and repackagers with 100 or fewer employees. The UDI rule doesn’t provide exceptions or delays based on company size.

Read the FDA’s de novo draft guidance here.

Read the FDA’s small entity UDI guidance here.

Filed Under: Food & Drug Administration (FDA), News Well, Pre-Market Approval (PMA), Regulatory/Compliance Tagged With: Unique Device Identifier (UDI)

More recent news

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy